Palaia I, Tomao F, Santangelo G, et al. - By retrospectively analyzing data from patients who were treated for ovarian cancer (OC) and having died in the period between 2007 and 2017, researchers inquired the frequency of antineoplastic treatments until the end of life, the chemotherapy-related toxicity, mortality, and the most frequent palliative care measure used. Following a median overall patient survival of 52.8 months, 110 OC deaths were analyzed. Chemotherapy was received over the last 3 months of life by 85 (77%) of the 110 patients analyzed, and even during the last month of life by 38%. Supportive therapies were required in the overwhelming majority of cases (81%). Deaths at home were reported in most of the cases, and 19% died in hospital, and only 4.5% died in hospice. In the last 30 days, a dramatic fall in the quality of life of these patients was reported, however, symptoms were improved by the best supportive care. Overall, end-of-life chemotherapy for OC patients was viewed as a thorny problem. In order to treat these patients in a better way, more investigations and a multidisciplinary approach are required.